Nahi et al [48] found evidence of dose-dependent apoptosis and cytotoxicity in CLL cells and suggested that ZNF331 is a small molecule that targets TP53, which could be useful for the treatment of drug-resistant leukemia. The gene discussed is ZNF331; the disease is B-cell chronic lymphocytic leukemia.